addS

Friday 17 April 2015

Non-Small Cell Lung Cancer Partnering 2010-2015 - Worldwide Industry size, share, trend, growth, analysis and Research Report

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

The Non-Small Cell Lung Cancer Partnering 2010-2015 report provides understanding and access to the non-small cell lung cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in non-small cell lung cancer partnering deals
Top non-small cell lung cancer deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

To Download Sample Report With TOC: http://www.researchmoz.com/enquiry.php?type=sample&repid=264378

The Non-Small Cell Lung Cancer Partnering 2010-2015 provides understanding and access to the non-small cell lung cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of non-small cell lung cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors non-small cell lung cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

To Browse a Full Report with TOC: http://www.researchmoz.us/non-small-cell-lung-cancer-partnering-2010-2015-report.html

This data driven report contains over 60 links to online copies of actual non-small cell lung cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of non-small cell lung cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of non-small cell lung cancer technologies and products.

Report scope

Non-Small Cell Lung Cancer Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to non-small cell lung cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in non-small cell lung cancer dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 60 non-small cell lung cancer deals and contract documents where available
The leading non-small cell lung cancer deals by value since 2010

In Non-Small Cell Lung Cancer Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


All Reports of this Category Here: http://www.researchmoz.us/diseases-conditions-market-reports-67.html


About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:


Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://dynamicmarketresearch.blogspot.com/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030

No comments:

Post a Comment